India has banned 328 combination drugs in order to prevent antibiotic resistance diseases from spreading and getting out of control. The banning of 328 drugs will hit the domestic and foreign pharmaceutical company’s bottom line.
Health activists have welcomed the move as antibiotic resistance grows due to the misuse and overuse of drugs. India in 2016 tried to ban 350 fixed-dose combinations (FDCs), but that decision was overturned by the Supreme Court calling for advisory board to make the final decision.
The board came to the conclusion that, “no therapeutic justification for the ingredients contained in 328 FDCs and that these FDCs may involve risk to human beings”. India statement regarding the 328 FDC was that it has official prohibited the manufacture and distribution of 328 FDC, with immediate effect.
The banning of these drugs is expected to impact a market worth $305 million a year, produced by both small and large pharmaceutical organizations. Combination drugs improve patient’s compliance, because it’s easier to get patients to take one drug rather than several.
Another problem India has is the lack of law enforcement, which led to proliferations of these drugs to over the limits that they are allowed to which also, adds on to the antibiotic resistance threat.